ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.'s Overview
ARIAD Pharmaceuticals, Inc. was a global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. Headquartered in Cambridge, Massachusetts, ARIAD was dedicated to the discovery, development, and commercialization of innovative therapies for rare cancers. Its research and development efforts led to significant advancements in treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with its drug Iclusig (ponatinib), and ALK-positive non-small cell lung cancer (NSCLC) with Alunbrig (brigatinib). In February 2017, ARIAD Pharmaceuticals was acquired by Takeda Pharmaceutical Company Limited, integrating ARIAD's strong oncology pipeline and talented personnel into Takeda's global oncology business unit.
Where is ARIAD Pharmaceuticals, Inc.'s Headquarters?
HQ Function
The headquarters served as the central hub for research and development, corporate operations, strategic management, and global commercialization efforts.
Notable Features:
The Cambridge facility was a state-of-the-art research and office space situated in Kendall Square, designed to foster collaboration and innovation within a vibrant biotech ecosystem.
Work Culture:
ARIAD cultivated a science-driven, patient-focused work culture. It emphasized innovation, rigorous scientific pursuit, collaboration, and a strong commitment to addressing unmet medical needs in oncology.
HQ Significance:
The Cambridge headquarters was pivotal to ARIAD's success, housing its core research laboratories and administrative functions, which enabled the discovery and development of its key cancer therapies, Iclusig and Alunbrig.
Values Reflected in HQ: The headquarters' prime location in a leading biotech hub and its advanced facilities reflected ARIAD's commitment to cutting-edge science, innovation, and its ambition to be a leader in oncology.
Location:
Prior to its acquisition by Takeda in 2017, ARIAD Pharmaceuticals had established a significant global presence, with a primary operational focus in North America and Europe. Its activities included global research and development programs, multinational clinical trials, and the commercialization of its oncology drugs in various countries. The company was actively pursuing strategies to broaden its reach to other key international markets to ensure its innovative cancer therapies were accessible to patients worldwide.
Street Address:
26 Landsdowne Street
City:
Cambridge
State/Province:
Massachusetts
Country:
USA
ARIAD Pharmaceuticals, Inc.'s Global Presence
Epalinges, Vaud, Switzerland
Address: ARIAD Pharmaceuticals (Europe) Sàrl, Route de la Corniche 4, CH-1066 Epalinges, Switzerland
To establish and expand ARIAD's presence in Europe, manage clinical trials across the continent, interact with the European Medicines Agency (EMA) and other national regulatory bodies, and commercialize approved therapies in European markets.
Buying Intent Signals for ARIAD Pharmaceuticals, Inc.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of ARIAD Pharmaceuticals, Inc.
As of April 2025, ARIAD Pharmaceuticals, Inc.' leadership includes:
Investors of ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
ARIAD Pharmaceuticals Inc. was acquired by Takeda in February 2017. Consequently, there have been no executive new hires or exits for ARIAD Pharmaceuticals Inc. as an independent standalone entity in the last 12 months. Any leadership changes pertaining to former ARIAD assets or personnel would occur within Takeda's organizational structure.
Technology (Tech Stack) used by ARIAD Pharmaceuticals, Inc.
Discover the tools ARIAD Pharmaceuticals, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ARIAD Pharmaceuticals, Inc. Email Formats and Examples
Prior to its 2017 acquisition by Takeda, ARIAD Pharmaceuticals, Inc. likely utilized standard corporate email formats. Based on common practices in the pharmaceutical industry, prevalent formats would typically include combinations of first name, last name, or initials with the company domain.
[first_initial][last_name]@ariad.com (e.g., jdoe@ariad.com) or [first_name].[last_name]@ariad.com (e.g., jane.doe@ariad.com). Note: ariad.com is no longer an active independent domain for ARIAD emails.
Format
jsmith@ariad.com or john.smith@ariad.com
Example
0 (domain no longer active for ARIAD post-acquisition; historically, these formats would have had a high success rate, e.g., 80%)%
Success rate
News and media
Takeda Press Release • January 9, 2017
ARIAD Pharmaceuticals Inc. News: Takeda to Acquire ARIAD Pharmaceuticals for $5.2 Billion, Strengthening Global Oncology Portfolio
Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. announced that they had entered into a definitive agreement under which Takeda would acquire all outstanding shares of ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion. The acquisition was intended to significantly enhance Takeda's oncology franchise with ARIAD's innovative targeted therapies, Iclusig (ponatinib) and the investigational brigatinib....more
Takeda Press Release • February 16, 2017
ARIAD Pharmaceuticals Inc. News: Takeda Completes Acquisition of ARIAD Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. Following the acquisition, ARIAD became an indirect wholly-owned subsidiary of Takeda. This strategic move was set to strengthen Takeda's position in oncology and expand its portfolio of cancer treatments....more
Takeda Press Release / FDA • April 28, 2017
ARIAD Pharmaceuticals Inc. Developed Drug News: FDA Grants Accelerated Approval to ALUNBRIG (brigatinib) for ALK-Positive Metastatic NSCLC
The U.S. Food and Drug Administration (FDA) granted accelerated approval to ALUNBRIG (brigatinib), a drug developed by ARIAD Pharmaceuticals, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The approval occurred shortly after Takeda's acquisition of ARIAD, marking a significant milestone for the brigatinib program....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including ARIAD Pharmaceuticals, Inc., are just a search away.